CEACAM5 and neoplasm: Interestingly, if the anti-CEA nanobody targets another epitope than the mAb, a combination of both fluorescent mAb and nanobody could enable a more rapid fluorescence of the tumour within hours to accelerate the patients’ care with a durable fluorescence signal useful for long surgery, such as pancreatic cancer resection.